Micropore appoints new CEO

Micropore appoints new CEO

Kay joins the company at a significant turning point for the company. Micropore is moving from an early proof-of-concept stage to a fully developed drug delivery solution.

Outgoing CEO Dai Hayward comments: “Having led Micropore from a new spinout to a global brand, I am excited to pass the baton to Kay while remaining in the business to continue the company's exciting growth in Asia Pacific. Kay's increased accuracy and compliance experience will mean Micropore will be able to meet the most demanding customer standards as the company embarks on its next chapter of growth.“

With over 20 years of senior leadership experience in the pharmaceutical industry (including large and mid-sized pharmaceutical companies and CDMOs), Kay is a values-driven and results-oriented leader who will bring extensive manufacturing, quality and leadership experience to the Micropore business.
In addition to his new role, which aims to build stronger commercial partnerships in Asia Pacific, Dai will chair a new scientific advisory board for the company.

We are pleased to welcome Kay to the Micropore team at such an exciting point in the company's growth journey, where he is setting the pace from development to manufacturing of complex pharmaceuticals for the latest cutting-edge nucleotide therapies utilizing lipid nanoparticles and controlled-release drugs. Having worked closely with Dai over the past seven years, I have admired his passion and drive for the company and now look forward to working with Kay as we advance Micropore in the next chapter of its evolution toward democratizing medicine.”

James Robson, Chairman, Micropore Technology

Sources: